{"generic":"Omeprazole\/Clarithromycin\/Amoxicillin","drugs":["Omeclamox-Pak","Omeprazole\/Clarithromycin\/Amoxicillin"],"mono":{"0":{"id":"jy50s0","title":"Generic Names","mono":"Omeprazole\/Clarithromycin\/Amoxicillin"},"1":{"id":"jy50s1","title":"Dosing and Indications","sub":[{"id":"jy50s1b4","title":"Adult Dosing","mono":"<b>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection:<\/b> Omeprazole 20 mg plus clarithromycin 500 mg plus amoxicillin 1000 mg ORALLY twice daily for 10 days; take in morning and evening prior to meals; give omeprazole 20 mg once daily for an additional 18 days if ulcer present at therapy initiation "},{"id":"jy50s1b5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients with Helicobacter pylori."},{"id":"jy50s1b6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment, severe (with or without coexisting hepatic impairment):<\/b> Consider extended dosing intervals for clarithromycin component.<\/li><li><b>Hepatic impairment:<\/b> Avoid use.<\/li><li><b>Geriatric:<\/b> No adjustment of omeprazole necessary; use caution with amoxicillin and consider monitoring renal function.<\/li><li><b>Patients of Asian descent:<\/b> Avoid use unless benefits outweigh risks<\/li><\/ul>"},{"id":"jy50s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection<br\/>"}]},"3":{"id":"jy50s3","title":"Contraindications\/Warnings","sub":[{"id":"jy50s3b9","title":"Contraindications","mono":"<ul><li>Concomitant ergotamine, dihydroergotamine, or pimozide use<\/li><li>Hypersensitivity to omeprazole, any macrolide antibiotics, penicillin, or any component of this product<\/li><\/ul>"},{"id":"jy50s3b10","title":"Precautions","mono":"<ul><li>Dermatologic:<\/li><li>-- Erythematosus skin rash has been reported in mononucleosis patients; use not recommended<\/li><li>Gastrointestinal:<\/li><li>-- Clostridium difficile-associated diarrhea has been reported, including cases occurring more than 2 months after administration; discontinue use and institute appropriate medical management if suspected or confirmed<\/li><li>-- Response to therapy does not rule out gastric malignancy<\/li><li>Hepatic:<\/li><li>-- Avoid use in patients with hepatic impairment<\/li><li>Immunologic:<\/li><li>-- Superinfections may occur; discontinue use<\/li><li>-- Drug-resistant bacteria may occur if administered in absence of proven or strongly suspected infection<\/li><li>Musculoskeletal:<\/li><li>-- New onset or worsening myasthenia gravis has been reported; monitoring recommended<\/li><li>Renal:<\/li><li>-- Acute interstitial nephritis has been reported; discontinue use<\/li><li>Other:<\/li><li>-- Avoid use in patients from Asian ancestry unless benefit outweighs risk.<\/li><\/ul>"},{"id":"jy50s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jy50s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jy50s4","title":"Drug Interactions","sub":[{"id":"jy50s4b13","title":"Contraindicated","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amifampridine (theoretical)<\/li><li>Astemizole (probable)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Colchicine (established)<\/li><li>Conivaptan (theoretical)<\/li><li>Dihydroergotamine (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Ergoloid Mesylates (probable)<\/li><li>Ergonovine (probable)<\/li><li>Ergotamine (probable)<\/li><li>Fluconazole (probable)<\/li><li>Isavuconazonium Sulfate (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Maraviroc (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Methylergonovine (probable)<\/li><li>Methysergide (probable)<\/li><li>Naloxegol (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nimodipine (theoretical)<\/li><li>Pimozide (probable)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rilpivirine (established)<\/li><li>Saquinavir (established)<\/li><li>Silodosin (probable)<\/li><li>Simvastatin (probable)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"jy50s4b14","title":"Major","mono":"<ul><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Ajmaline (theoretical)<\/li><li>Alprazolam (established)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amlodipine (established)<\/li><li>Amobarbital (theoretical)<\/li><li>Amprenavir (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprepitant (probable)<\/li><li>Aprindine (theoretical)<\/li><li>Aprobarbital (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atazanavir (established)<\/li><li>Atorvastatin (probable)<\/li><li>Avanafil (theoretical)<\/li><li>Axitinib (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Bendamustine (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Butabarbital (theoretical)<\/li><li>Butalbital (theoretical)<\/li><li>Cabazitaxel (established)<\/li><li>Cabozantinib (theoretical)<\/li><li>Carbamazepine (established)<\/li><li>Ceritinib (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlortetracycline (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clonazepam (theoretical)<\/li><li>Clopidogrel (established)<\/li><li>Clorazepate (probable)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabigatran Etexilate (established)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Demeclocycline (probable)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Digoxin (established)<\/li><li>Diltiazem (established)<\/li><li>Disopyramide (probable)<\/li><li>Docetaxel (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Doxycycline (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Dutasteride (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Efavirenz (established)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erlotinib (probable)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Estazolam (established)<\/li><li>Eszopiclone (theoretical)<\/li><li>Etravirine (probable)<\/li><li>Everolimus (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Felodipine (established)<\/li><li>Fentanyl (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (probable)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibrutinib (theoretical)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Indinavir (established)<\/li><li>Irinotecan (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ixabepilone (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Ledipasvir (theoretical)<\/li><li>Letrozole (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Losartan (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Lymecycline (probable)<\/li><li>Macitentan (theoretical)<\/li><li>Meclocycline (probable)<\/li><li>Mefloquine (theoretical)<\/li><li>Mephobarbital (theoretical)<\/li><li>Methacycline (probable)<\/li><li>Methadone (theoretical)<\/li><li>Methohexital (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Metronidazole (theoretical)<\/li><li>Midazolam (established)<\/li><li>Mifepristone (theoretical)<\/li><li>Minocycline (probable)<\/li><li>Mitotane (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Modafinil (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Mycophenolate Mofetil (established)<\/li><li>Nafarelin (theoretical)<\/li><li>Nafcillin (theoretical)<\/li><li>Nicardipine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Nisoldipine (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Ospemifene (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Oxycodone (established)<\/li><li>Oxytetracycline (probable)<\/li><li>Palbociclib (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Paroxetine (probable)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (established)<\/li><li>Pentamidine (theoretical)<\/li><li>Pentobarbital (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pipamperone (theoretical)<\/li><li>Pirmenol (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Retapamulin (theoretical)<\/li><li>Rifabutin (established)<\/li><li>Rifapentine (probable)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (established)<\/li><li>Roflumilast (theoretical)<\/li><li>Rolitetracycline (probable)<\/li><li>Romidepsin (theoretical)<\/li><li>Ruxolitinib (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Secobarbital (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sildenafil (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tadalafil (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tetracycline (probable)<\/li><li>Thiopental (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolterodine (probable)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (established)<\/li><li>Triazolam (established)<\/li><li>Trimethoprim (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Verapamil (established)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vinblastine (probable)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Vinorelbine (established)<\/li><li>Vismodegib (theoretical)<\/li><li>Vorapaxar (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><li>Warfarin (probable)<\/li><li>Zaleplon (theoretical)<\/li><li>Zidovudine (probable)<\/li><li>Zileuton (theoretical)<\/li><li>Zolpidem (theoretical)<\/li><\/ul>"},{"id":"jy50s4b15","title":"Moderate","mono":"<ul><li>Acenocoumarol (probable)<\/li><li>Alfentanil (probable)<\/li><li>Armodafinil (probable)<\/li><li>Bromocriptine (probable)<\/li><li>Conjugated Estrogens (probable)<\/li><li>Cranberry (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Darunavir (established)<\/li><li>Diazepam (probable)<\/li><li>Disulfiram (probable)<\/li><li>Esterified Estrogens (probable)<\/li><li>Estradiol (probable)<\/li><li>Estriol (probable)<\/li><li>Estrone (probable)<\/li><li>Estropipate (probable)<\/li><li>Ethinyl Estradiol (probable)<\/li><li>Ginkgo Biloba (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (established)<\/li><li>Hexobarbital (probable)<\/li><li>Iron (probable)<\/li><li>Khat (probable)<\/li><li>Levothyroxine (probable)<\/li><li>Linezolid (probable)<\/li><li>Methylprednisolone (probable)<\/li><li>Nevirapine (established)<\/li><li>Pravastatin (probable)<\/li><li>Prednisone (probable)<\/li><li>Probenecid (probable)<\/li><li>Raltegravir (established)<\/li><li>Repaglinide (probable)<\/li><li>Rifampin (established)<\/li><li>Rivaroxaban (established)<\/li><li>Tipranavir (established)<\/li><\/ul>"}]},"5":{"id":"jy50s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain, Diarrhea (14%), Disorder of taste (10%), Flatulence, Nausea, Vomiting<\/li><li><b>Neurologic:<\/b>Headache (7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval, Torsades de pointes, Ventricular arrhythmia, Ventricular tachycardia<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea, Pancreatitis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Hemolytic anemia, Pancytopenia<\/li><li><b>Hepatic:<\/b>Hepatotoxicity<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Renal:<\/b>Interstitial nephritis, acute<\/li><\/ul>"},"6":{"id":"jy50s6","title":"Drug Name Info","sub":{"0":{"id":"jy50s6b17","title":"US Trade Names","mono":"Omeclamox-Pak<br\/>"},"2":{"id":"jy50s6b19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Macrolide<\/li><li>Penicillin, Aminopenicillin<\/li><li>Proton Pump Inhibitor<\/li><\/ul>"},"3":{"id":"jy50s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jy50s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jy50s7","title":"Mechanism Of Action","mono":"Omeprazole inhibits the H+\/K+ ATPase enzyme system of the gastric parietal cell, which suppresses gastric acid secretion. Omeprazole also has anti-bacterial activity in certain culture conditions. Clarithromycin is a macrolide class antibiotic that binds to the 50S ribosomal subunit thus inhibiting protein synthesis. Amoxicillin is a beta-lactam antibiotic that inhibits biosynthesis of cell wall mucopeptides.<br\/>"},"8":{"id":"jy50s8","title":"Pharmacokinetics","sub":[{"id":"jy50s8b23","title":"Absorption","mono":"<ul><li>Amoxicillin, Tmax, Oral: 1 to 2 hours<\/li><li>Clarithromycin, Tmax, Oral: 2 to 3 hours<\/li><li>Omeprazole delayed-release capsule, Tmax, Oral: 0.5 to 3.5 hours<\/li><li>Amoxicillin, Bioavailability, Oral: Rapid<\/li><li>Clarithromycin, Bioavailability, Oral: 50%<\/li><li>Omeprazole, Bioavailability, Oral: 30% to 40%<\/li><li>Amoxicillin, Effects of Food: No effect<\/li><li>Clarithromycin, Effects of Food: No clinically significant effect<\/li><li>Omeprazole delayed-release capsule, Effects of Food: Cmax decreased 25% (20 mg); no effect (40 mg)<\/li><\/ul>"},{"id":"jy50s8b24","title":"Distribution","mono":"<ul><li>Amoxicillin, Protein binding: 20%<\/li><li>Omeprazole, Protein binding: 95%<\/li><\/ul>"},{"id":"jy50s8b25","title":"Metabolism","mono":"<ul><li>Omeprazole, Hepatic: Extensive via CYP450<\/li><li>Clarithromycin, 14-OH clarithromycin: Active<\/li><\/ul>"},{"id":"jy50s8b26","title":"Excretion","mono":"<ul><li>Amoxicillin, Renal: 60%, primarily unchanged<\/li><li>Clarithromycin, Renal: 30% unchanged; 10% to 15% as metabolite<\/li><li>Clarithromycin, Renal clearance: Approximates GFR<\/li><li>Omeprazole, Bile: Significant (metabolites)<\/li><li>Omeprazole, Fecal: 23%<\/li><li>Omeprazole, Renal: 77%, primarily as metabolites<\/li><li>Omeprazole, Total body clearance: 500 to 600 mL\/min<\/li><\/ul>"},{"id":"jy50s8b27","title":"Elimination Half Life","mono":"<ul><li>Amoxicillin: 61.3 minutes<\/li><li>Clarithromycin: 5 to 7 hours<\/li><li>14-OH clarithromycin: 7 to 9 hours<\/li><li>Omeprazole: 0.5 to 1 hour<\/li><\/ul>"}]},"9":{"id":"jy50s9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Take twice daily (4 pills per dose) prior to morning and evening meals.<\/li><li>Swallow all pills whole, do not crush or chew.<\/li><\/ul>"},"10":{"id":"jy50s10","title":"Monitoring","mono":"<ul><li>Helicobacter pylori susceptibility to clarithromycin testing, in patients who fail therapy<\/li><li>Eradication of H. pylori bacteria is indicative of efficacy.<\/li><li>Renal function, in elderly patients<\/li><li>Signs and symptoms of myasthenia gravis, during treatment<\/li><\/ul>"},"11":{"id":"jy50s11","title":"How Supplied","mono":"<b>Omeclamox-Pak<\/b><br\/>KIT: (Amoxicillin;Clarithromycin;OmeprazoleAmoxicillin;Clarithromycin;OmeprazoleAmoxicillin;Clarithromycin;Omeprazole) 500 MG,500 MG,20 MG<br\/>"},"12":{"id":"jy50s12","title":"Toxicology","sub":[{"id":"jy50s12b31","title":"Clinical Effects","mono":"<ul><li><b>MACROLIDE ANTIBIOTICS <\/b><br\/>OVERDOSE: Significant toxicity following acute overdose is uncommon.  N\/V, abdominal pain may occur.  ADVERSE EFFECTS: N\/V, abdominal pain, diarrhea most common.  Cholestasis, sensorineural hearing loss, thrombophlebitis (IV administration), ventricular dysrhythmias\/QT prolongation (IV administration) are less common.<br\/><\/li><li><b>OMEPRAZOLE AND RELATED AGENTS <\/b><br\/>USES: Dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole are substituted benzimidazoles and potent proton-pump inhibitors used as gastric antisecretories.  They are used to treat various gastrointestinal conditions (eg, dyspepsia, gastroesophageal reflux disease (GERD), duodenal and peptic ulcers, and esophageal stricture).  Esomeprazole with naproxen and omeprazole with sodium bicarbonate combinations are also available. Refer to &quot;NAPROXEN&quot; and &quot;SODIUM BICARBONATE&quot; management for specific information. PHARMACOLOGY: These agents inhibit the parietal cell membrane enzyme (H+\/K+)-ATPase, typically referred to as the proton pump, which blocks the final step of acid production. EPIDEMIOLOGY: Overdose is rare, and only mild toxicity has been reported. OVERDOSE: Overdose effects are anticipated to be an extension of adverse effects observed following therapeutic doses. In limited overdose cases, clinical effects have consisted of mild tachycardia, flushing, somnolence, confusion, headache, blurred vision, abdominal pain, nausea, vomiting, dry mouth, and moderate leukocytosis. ADVERSE EFFECTS: Proton-pump inhibitors have similar adverse events reported after therapeutic use. COMMON (2% or greater): Headache, abdominal pain, nausea, vomiting, diarrhea, and flatulence. OTHER EFFECTS: Constipation, dry mouth, hypertension, and dizziness. RARE: Lichen spinulosus, exfoliative dermatitis, toxic epidermal necrolysis, cutaneous leukocytoclastic vasculitis, urticaria, anaphylaxis, hypomagnesemia, pancreatitis, elevated serum creatinine levels, anterior ischemic optic neuropathy, optic neuritis, optic atrophy, neutropenia, agranulocytosis, thrombocytopenia, pancytopenia, hemolytic anemia, elevated liver enzymes, hepatitis, hepatic encephalopathy, rhabdomyolysis, myopathy, hypocalcemic-induced seizures. ACUTE INTERSTITIAL NEPHRITIS: Although rare, acute interstitial nephritis (AIN) has been reported in association with all proton-pump inhibitors (PPIs).  The mean duration of treatment prior to onset of symptoms is reported at 9 to 13 weeks.  A decline in renal function is usually noted over a period of days to weeks. Fatigue, malaise, weakness, nausea, vomiting, anorexia, and weight loss are commonly reported symptoms.  Classic drug hypersensitivity signs and symptoms, such as the clinical triad of rash, fever and eosinophilia, are seen in less than 10% of patients.<br\/><\/li><li><b>PENICILLIN<\/b><br\/>USES: Penicillins are used to treat gram-negative bacilli that can include second-generation (eg, ampicillin, amoxicillin), third-generation (eg, carbenicillin and ticarcillin), and fourth-generation penicillins (eg, piperacillin). PHARMACOLOGY: Penicillin is derived from the fungus penicillum. As a class, penicillins contain a 6 aminopenicillanic acid nucleus, composed of a beta-lactam ring fused to a 5 member thiazolidine ring. Penicillins and other beta-lactams inhibit cell wall mucopeptide synthesis. TOXICOLOGY: A penicillin can act as an agonist at the picrotoxin binding site causing GABA antagonism, CNS excitation and seizures. High doses of amoxicillin can cause crystal precipitation in the urine, with hematuria and renal insufficiency. EPIDEMIOLOGY: Penicillin overdose is relatively uncommon, but has the potential to produce severe toxicity. MILD TO MODERATE TOXICITY: Nausea, vomiting, abdominal pain and diarrhea may develop with ingestion. Skin rashes and urticaria may develop, especially with amoxicillin and ampicillin ingestions. Hematuria, crystalluria and transient renal insufficiency have been reported after amoxicillin overdose. SEVERE TOXICITY: Agitation, confusion, hallucinations, stupor, coma, multifocal myoclonus, seizures and encephalopathy may occur following massive doses of IV penicillins (40 to 100 million units\/day). Cardiac arrest and death have been associated with inadvertent intravenous administration of penicillin G (benzathine and procaine). Hyperkalemia may also develop. ADVERSE EFFECTS: COMMON: GASTROINTESTINAL: Nausea, vomiting, diarrhea, epigastric distress, and black hairy tongue are likely with orally administered penicillins. RENAL: Renal failure, crystalluria, interstitial nephritis, and hemorrhagic cystitis have been reported following the use of penicillin derivatives.Symptoms are frequently associated with sensitivity reactions and may include the following: DERMATOLOGY: Dermatologic reactions can vary greatly in severity, character, and distribution.  Amoxicillin and ampicillin appears to cause skin rashes more frequently than other penicillins. HEMATOLOGIC: Thrombocytopenia, neutropenia, and agranulocytosis have occurred following administration of the semisynthetic penicillins and may be related to a hypersensitivity reaction. SEVERE: Anaphylaxis may follow an exposure to any amount of penicillin; severe hypersensitivity reactions may result in anaphylaxis. Parenteral exposures are more likely to cause severe allergic reactions compared to an oral exposure. RARE: Penicillin-induced granulocytopenia is rare and has been associated with high-dose parenteral therapy.<br\/><\/li><\/ul>"},{"id":"jy50s12b32","title":"Treatment","mono":"<ul><li><b>MACROLIDE ANTIBIOTICS <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Therapy as indicated.<\/li><li>Abdominal discomfort: Food, milk or an antacid  may be given; most effects reverse with drug cessation<\/li><li>Monitoring of patient: Baseline ECG, cardiac monitoring as indicated. Renal and hepatic function as indicated.<\/li><\/ul><\/li><li><b>OMEPRAZOLE AND RELATED AGENTS <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treatment is symptomatic and supportive. Correct any significant fluid and\/or electrolyte abnormalities in patients with severe diarrhea and\/or vomiting. MANAGEMENT OF SEVERE TOXICITY: Treatment is symptomatic and supportive. Significant toxicity is not expected after an overdose.<\/li><li>Decontamination: PREHOSPITAL:  Prehospital gastrointestinal decontamination is generally not required.  HOSPITAL: Severe toxicity is not expected after an overdose. Gastrointestinal decontamination is generally not necessary. Consider activated charcoal only if coingestants with significant toxicity are involved.<\/li><li>Airway management: Ensure adequate ventilation and perform endotracheal intubation early in patients with severe allergic reactions.<\/li><li>Antidote: None.<\/li><li>Hypersensitivity reaction: MILD\/MODERATE: Antihistamines with or without inhaled beta agonists, corticosteroids or epinephrine. SEVERE: Oxygen, aggressive airway management, antihistamines, epinephrine, corticosteroids, ECG monitoring, and IV fluids.<\/li><li>Monitoring of patient: No specific laboratory tests are necessary unless otherwise clinically indicated. Monitor serum electrolytes in patients with significant vomiting and\/or diarrhea. Monitor vital signs, CBC with differential, renal function, CK, and liver enzymes in symptomatic patients.<\/li><li>Enhanced elimination procedure: Hemodialysis is UNLIKELY to be of value because of the high degree of protein binding and large volume of distribution of these agents.<\/li><li>Patient disposition: HOME CRITERIA: A patient with an inadvertent exposure, that remains asymptomatic can be managed at home. OBSERVATION CRITERIA: Patients with a deliberate overdose, and those who are symptomatic, need to be monitored for several hours to assess electrolyte and fluid balance. Patients that remain asymptomatic can be discharged. ADMISSION CRITERIA: Patients should be admitted for severe vomiting, profuse diarrhea, severe abdominal pain, dehydration, and electrolyte abnormalities.  CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity or in whom the diagnosis is not clear.<\/li><\/ul><\/li><li><b>PENICILLIN <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treatment is symptomatic and supportive. Treat significant vomiting and diarrhea with IV fluids; administer antiemetics, as needed. HYPERSENSITIVITY REACTION: Administer antihistamines, with or without inhaled beta agonists, corticosteroids or epinephrine. MANAGEMENT OF SEVERE TOXICITY: ANAPHYLAXIS: Acute anaphylaxis is more likely to occur after parenteral exposure, but may develop with all routes. Administer oxygen, aggressive airway management, antihistamines, epinephrine, corticosteroids, ECG monitoring, and IV fluids. Dysrhythmias should be treated with standard antiarrhythmic drugs, if necessary. SEIZURES: Initially treat with IV benzodiazepines.<\/li><li>Decontamination: PREHOSPITAL: Gastric decontamination is unlikely to be necessary in most ingestions. HOSPITAL: GI decontamination is unlikely to be necessary, administer activated charcoal if the ingestion is recent and toxic coingestants are involved.<\/li><li>Airway management: Airway management is unlikely to be needed following an overdose; however, aggressive airway management is indicated in patients that develop a significant hypersensitivity\/anaphylactoid reaction.<\/li><li>Antidote: There is no known antidote.<\/li><li>Monitoring of patient: Monitor vital signs and mental status. Monitor renal function, urinalysis, and electrolytes following a significant overdose. Monitor fluid status in patients with severe vomiting and\/or diarrhea. Obtain a baseline ECG and institute continuous cardiac monitoring in patients with a significant IV overdose. Plasma levels of these antibiotics are not clinically useful in overdose situations.<\/li><li>Enhanced elimination procedure: HEMODIALYSIS: Ampicillin-class antibiotics, amoxicillin and ticarcillin are removed from the circulation by hemodialysis, but as severe toxicity is highly unlikely hemodialysis is almost never indicated.<\/li><li>Intrathecal injection: Intrathecal injection has occurred rarely with penicillins. Treat seizures aggressively (benzodiapzepines, barbiturates, propofol). Cerebrospinal fluid (CSF) drainage and CSF exchange may be useful after a large overdose. The following information is derived from limited case reports and experience with antineoplastic agents. Keep the patient upright if possible. Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults.  Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free normal saline or lactated ringers).  Consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline or LR through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 to 150 mL\/hr for 18 to 24 hours). Dexamethasone 4 mg IV every 6 hours to prevent arachnoiditis.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic children with inadvertent ingestions of pediatric preparations can generally be managed at home. A small number of children ingesting more than 250 mg\/kg of amoxicillin have developed crystalluria, hematuria and transient renal insufficiency; any patient who develops urinary symptoms should be referred to a healthcare facility. OBSERVATION CRITERIA: Patients with deliberate overdose or with more than mild symptoms should be evaluated in a health care facility. All patients with a history of penicillin allergy or evidence of a hypersensitivity reaction should be referred immediately to a healthcare facility. Patients should be observed until symptoms resolve and clinical parameters (eg, vital signs, mental status) are within normal limits. ADMISSION CRITERIA: Patients with ongoing symptoms should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in patients with persistent renal or cardiovascular symptoms.<\/li><\/ul><\/li><\/ul>"},{"id":"jy50s12b33","title":"Range of Toxicity","mono":"<ul><li><b>MACROLIDE ANTIBIOTICS<\/b><br\/>In general, the macrolide antibiotics are of a low order toxicity.<br\/><\/li><li><b>OMEPRAZOLE AND RELATED AGENTS<\/b><br\/>TOXICITY: OMEPRAZOLE: Doses up to 2400 mg (120 times the usual recommended clinical dose) resulted in transient effects (eg, drowsiness, confusion, and tachycardia), with no serious events reported when taken alone. LANSOPRAZOLE: An adult ingested 600 mg with no adverse events reported. In animal studies, oral doses up to 1300 times the recommended human dose did not produce any deaths or clinical events.  RABEPRAZOLE: The maximum reported overdose with rabeprazole was 80 mg. There were no clinical signs or symptoms associated with any reported overdose. Patients with Zollinger-Ellison syndrome have been treated with doses up to 120 mg rabeprazole once daily. THERAPEUTIC DOSE: Varies by indication: DEXLANSOPRAZOLE: Adults: 30 mg or 60 mg once daily. Children: Safety and efficacy not established. ESOMEPRAZOLE: Adults and children 12 to 17 years of age: 20 mg or 40 mg orally once daily. Children 1 to 11 years of age: 10 mg orally once daily (weight less than 20 kg); 10 to 20 mg orally once daily (weight 20 kg or more); 1 month to less than 1 year of age: 2.5 to 10 mg for patients weighing 3 to 12 kg; less than 1 month of age: Safety and efficacy not established. LANSOPRAZOLE: Adults: 15 mg or 30 mg once daily. Children: Varies by weight and age: 15 mg to 30 mg once daily. OMEPRAZOLE: Adults: 20 to 60 mg orally once daily. Children 1 to 16 years of age: 5 mg once daily (weight 5 to less than 10 kg); 10 mg once daily (weight 10 to less than 10 kg); 20 mg once daily (weight 20 kg or greater). Children: 20 to 40 mg orally once daily. RABEPRAZOLE: Adults and children 12 years and older: 20 mg once daily.<br\/><\/li><li><b>PENICILLIN <\/b><br\/>TOXICITY: A specific toxic dose has not been established. INTRAVENOUS: Agitation, confusion, hallucinations, stupor, coma multifocal myoclonus, seizures and encephalopathy may occur following massive doses of IV penicillins (40 to 100 million units\/day); patients with renal impairment may be at increased risk. AMOXICILLIN: ORAL: Serious toxicity is unlikely following large oral doses of amoxicillin. Acute renal failure has been described in a 3-year-old boy who ingested 574 mg\/kg of amoxicillin. Toxicity is unlikely with doses of 250 mg\/kg or less. THERAPEUTIC DOSE: SELECT AGENTS: AMOXICILLIN: ADULT: Up to 875 mg orally every 12 hours for severe infections; PEDIATRIC: ACUTE OTITIS MEDIA: CHILDREN 2 MONTHS OF AGE AND OLDER: 80 to 90 mg\/kg\/day orally in 2 to 3 divided doses for 5 to 7 days (or 10 days in children less than 6 years of age or severe illness). AMPICILLIN: ADULT: Various infections: Weighing 40 kg or greater: 500 mg IV\/IM every 6 hours; Weighing less than 40 kg: 50 mg\/kg\/day at 6 to 8 hour intervals; PEDIATRIC: Various infections: 150 to 200 mg\/kg\/day in equally divided doses every 3 to 4 hours. PENICILLIN G SODIUM: ADULT: Serious infections: 5 to 24 million units\/day in equally divided doses every 4 to 6 hours, depending on the infection and its severity; PEDIATRIC: This agent is NOT indicated in children requiring less than one million units per dose. PENICILLIN G BENZATHINE: ADULT: 2,400,000 units as a single dose or once daily for 2 to 3 days as indicated; PEDIATRIC: Varies by infection: Under 30 lbs: 600, 000 units as a single dose; 30 to 60 lbs: 900,000 units as a single dose; over 60 lbs: 2,400,000 units as a single dose.<br\/><\/li><\/ul>"}]},"13":{"id":"jy50s13","title":"Clinical Teaching","mono":"<ul><li>Drug may decrease effectiveness of oral contraceptives with concurrent use. Recommend additional form of birth control.<\/li><li>This drug may cause diarrhea, nausea, vomiting, or rash.<\/li><li>Advise patient to immediately report signs\/symptoms of hepatotoxicity or Clostridium difficile-associated diarrhea (severe, watery, or bloody diarrhea).<\/li><li>This drug may cause abdominal pain, taste disorder, dyspepsia, nausea, diarrhea, or headache.<\/li><li>Patient should take extended-release tablets with food.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><li>Advise patient that drug may increase risk for osteoporosis-related fractures of the hip, wrist, or spine with multiple daily doses that are continued for longer than a year.<\/li><li>Warn patient to report diarrhea that does not improve, especially with persistent watery stools, fever, and abdominal pain.<\/li><li>Drug may cause abdominal pain, diarrhea, nausea, vomiting, flatulence, headaches, and fever (children).<\/li><li>Warn patient to immediately report signs\/symptoms of hypomagnesemia, including palpitations, dizziness, seizures, or involuntary muscle contractions.<\/li><li>Advise patient to take drug at least 1 hour before a meal.<\/li><li>Instruct patient using oral suspension to mix the powder with water and to take the mixture or give via nasogastric\/gastric tube within 30 minutes.<\/li><li>Counsel patient who is unable to swallow the capsule whole to sprinkle the contents of the capsule onto a tablespoon of applesauce and swallow immediately.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult a healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}